Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Grows By 104.1%

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totaling 1,130,000 shares, agrowthof104.1% from the July 31st total of 553,600 shares. Based on an average daily trading volume, of 2,490,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately6.1% of the company’s stock are short sold. Approximately6.1% of the company’s stock are short sold. Based on an average daily trading volume, of 2,490,000 shares, the days-to-cover ratio is currently 0.5 days.

iBio Price Performance

Shares of NYSEAMERICAN:IBIO opened at $0.84 on Friday. The company’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $1.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a one year low of $0.56 and a one year high of $6.89.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.